B Acres

Summary

Affiliation: Transgene SA
Country: France

Publications

  1. pmc Type I IFN innate immune response to adenovirus-mediated IFN-gamma gene transfer contributes to the regression of cutaneous lymphomas
    Mirjana Urosevic
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    J Clin Invest 117:2834-46. 2007
  2. ncbi MUC1-specific immune responses in human MUC1 transgenic mice immunized with various human MUC1 vaccines
    B Acres
    Department of Immunobiology, Transgene SA, Strasbourg, France
    Cancer Immunol Immunother 48:588-94. 2000
  3. ncbi Secretomers as a new tool for the monitoring of CTL responses
    Bastien Calmels
    Transgene S A, Molecular Immunology Laboratory, Strasbourg, 67082, France
    Cancer Immunol Immunother 54:548-56. 2005
  4. ncbi MUC1 as a target antigen for cancer immunotherapy
    Bruce Acres
    Department of Medical and Regulatory Affairs, Transgene, 67082 Strasbourg, France
    Expert Rev Vaccines 4:493-502. 2005
  5. ncbi Cancer immunotherapy: phase II clinical studies with TG4010 (MVA-MUC1-IL2)
    Bruce Acres
    Transgene, Strasbourg, France
    J BUON 12:S71-5. 2007
  6. ncbi Discovery and development of therapeutic cancer vaccines
    Bruce Acres
    Transgene SA, Department of Medical Affairs, 11 rue de Molsheim, 67082 Strasbourg, France
    Curr Opin Drug Discov Devel 10:185-92. 2007
  7. doi Clinical development of MVA-based therapeutic cancer vaccines
    Bruce Acres
    Transgene SA, Strasbourg, Cedex 67082, France, Transgene SA, Strasbourg, Cedex 67082, France
    Expert Rev Vaccines 7:889-93. 2008
  8. ncbi Specific tumor cell targeting by a recombinant MVA expressing a functional single chain antibody on the surface of intracellular mature virus (IMV) particles
    Stephane Paul
    Molecular Immunology Laboratory, Strasbourg, France
    Viral Immunol 20:664-71. 2007
  9. ncbi Fusokine interleukin-2/interleukin-18, a novel potent innate and adaptive immune stimulator with decreased toxicity
    Bruce Acres
    Division of Medical and Regulatory Affairs, Molecular Immunology Laboratory, Histology and Animal Facilities Laboratory, Transgene SA, Strasbourg, France
    Cancer Res 65:9536-46. 2005
  10. ncbi [MUC1, a therapeutic target in oncology]
    Jean Marc Limacher
    Transgene SA, 11, rue de Molsheim, 67082 Strasbourg Cedex
    Bull Cancer 94:253-7. 2007

Detail Information

Publications23

  1. pmc Type I IFN innate immune response to adenovirus-mediated IFN-gamma gene transfer contributes to the regression of cutaneous lymphomas
    Mirjana Urosevic
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    J Clin Invest 117:2834-46. 2007
    ..Biological effects of type I IFNs seem to enhance those set in motion by the transgene, in our case IFN-gamma. This combination may prove to be of therapeutic importance in cytokine gene transfer using Ads...
  2. ncbi MUC1-specific immune responses in human MUC1 transgenic mice immunized with various human MUC1 vaccines
    B Acres
    Department of Immunobiology, Transgene SA, Strasbourg, France
    Cancer Immunol Immunother 48:588-94. 2000
    ..These results suggest that it is possible to generate an immune response to a cancer-related antigen without damage to normal tissues expressing the antigen...
  3. ncbi Secretomers as a new tool for the monitoring of CTL responses
    Bastien Calmels
    Transgene S A, Molecular Immunology Laboratory, Strasbourg, 67082, France
    Cancer Immunol Immunother 54:548-56. 2005
    ..Infection of tumor cells with these adenovirus constructs results in the secretion of the complexes into the culture supernatant. These soluble divalent class I MHC molecules were used to detect and activate specific CTL populations...
  4. ncbi MUC1 as a target antigen for cancer immunotherapy
    Bruce Acres
    Department of Medical and Regulatory Affairs, Transgene, 67082 Strasbourg, France
    Expert Rev Vaccines 4:493-502. 2005
    ....
  5. ncbi Cancer immunotherapy: phase II clinical studies with TG4010 (MVA-MUC1-IL2)
    Bruce Acres
    Transgene, Strasbourg, France
    J BUON 12:S71-5. 2007
    ..A second gene, interleukin-2 is also incorporated into TG4010 as an immune stimulus. The vaccine has been tested in breast, kidney, prostate and lung cancers with encouraging results...
  6. ncbi Discovery and development of therapeutic cancer vaccines
    Bruce Acres
    Transgene SA, Department of Medical Affairs, 11 rue de Molsheim, 67082 Strasbourg, France
    Curr Opin Drug Discov Devel 10:185-92. 2007
    ..This review describes antigen-specific therapeutic cancer vaccines that are currently in development...
  7. doi Clinical development of MVA-based therapeutic cancer vaccines
    Bruce Acres
    Transgene SA, Strasbourg, Cedex 67082, France, Transgene SA, Strasbourg, Cedex 67082, France
    Expert Rev Vaccines 7:889-93. 2008
    ..In this article, we describe the clinical use of vaccinia virus, in particular modified vaccinia virus Ankara (MVA), to express TAAs in vivo and to stimulate an effective immune response to the cancer antigens...
  8. ncbi Specific tumor cell targeting by a recombinant MVA expressing a functional single chain antibody on the surface of intracellular mature virus (IMV) particles
    Stephane Paul
    Molecular Immunology Laboratory, Strasbourg, France
    Viral Immunol 20:664-71. 2007
    ..The construct containing the antibody was able to bind a MUC-1 specific 60mer peptide. Moreover, targeted virus infects MUC-1-expressing cells in vitro more efficiently...
  9. ncbi Fusokine interleukin-2/interleukin-18, a novel potent innate and adaptive immune stimulator with decreased toxicity
    Bruce Acres
    Division of Medical and Regulatory Affairs, Molecular Immunology Laboratory, Histology and Animal Facilities Laboratory, Transgene SA, Strasbourg, France
    Cancer Res 65:9536-46. 2005
    ..Both innate and adaptive effector mechanisms are required for this antitumor activity...
  10. ncbi [MUC1, a therapeutic target in oncology]
    Jean Marc Limacher
    Transgene SA, 11, rue de Molsheim, 67082 Strasbourg Cedex
    Bull Cancer 94:253-7. 2007
    ..These cancer-associated changes render it antigenic and make it an attractive target for a specific cancer immunotherapy. Several MUC1-based therapeutic cancer vaccines are currently under clinical investigation...
  11. ncbi Bypassing tumor-associated immune suppression with recombinant adenovirus constructs expressing membrane bound or secreted GITR-L
    Bastien Calmels
    Molecular Immunology Laboratory, Transgene SA, Strasbourg 67082, France
    Cancer Gene Ther 12:198-205. 2005
    ..The virus constructs were injected into growing B16 melanoma tumors. Ad-GITR-L was shown to attract infiltration with both CD4+ and CD8+ T cells. Both constructs were shown to inhibit tumor growth...
  12. pmc Gene-based vaccines and immunotherapeutics
    Margaret Liu
    Transgene, 11 rue de Molsheim, 67082 Strasbourg, France
    Proc Natl Acad Sci U S A 101:14567-71. 2004
    ..Both are encoded by a highly attenuated vaccinia virus vector [modified vaccinia Ankara (MVA)] and both are coexpressed with IL-2. Encouraging results seen in both of these programs are described...
  13. ncbi Therapeutic cancer vaccines
    Bruce Acres
    Transgene SA, 11 rue de Molsheim, 67082 Strasbourg, France
    Curr Opin Mol Ther 6:40-7. 2004
    ..Aggressive protocols such as those combining specific stimulation of T-cells and chemotherapy or strategies to block immune regulation are having some success...
  14. ncbi Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity
    P Slos
    Transgene SA, Strasbourg 67085, France
    Cancer Gene Ther 8:321-32. 2001
    ..Finally, mice preimmunized with Ad-null viruses were severely compromised in their capacity to eradicate established P815 tumors after Ad-pCMV-IL-2 therapy, at least when neutralizing antibody titers reached a critical level...
  15. ncbi Cancer vaccines: challenges and outlook in the field
    Stephane Paul
    Transgene SA, Research and Development, 11 rue de Molsheim, 67082 Strasbourg, France
    IDrugs 10:324-8. 2007
    ..This feature review considers strategies for the development of effective therapeutic cancer vaccines, and highlights select vaccines that have already entered the clinic...
  16. ncbi Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer
    Allan J Pantuck
    Department of Urology, David Geffen School of Medicine at University of California, Los Angeles 90095, USA
    J Immunother 27:240-53. 2004
    ..These results suggest that VV/MUC-1/IL-2 gene therapy with a maximum tolerated dose of 5 x 10(7) pfu is safe and well tolerated...
  17. ncbi Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: phase II randomized study comparing two dose levels
    Christoph Rochlitz
    Departement Innere Medizin, Abteilung für Onkologie, Kantonsspital, Petersgraben 4, CH 4031 Basel, Switzerland
    Cancer Gene Ther 9:289-95. 2002
    ..The objectives of this study were to evaluate the tolerance and incidence of tumor regression in patients with metastatic melanoma, following repeated administration of Vero-IL-2 cells...
  18. ncbi Adenovirus-mediated intralesional interferon-gamma gene transfer induces tumor regressions in cutaneous lymphomas
    Reinhard Dummer
    Department of Dermatology, University Hospital Zurich, Gloriastrasse 31, 8091 Zurich, Switzerland
    Blood 104:1631-8. 2004
    ..We demonstrate the induction of humoral immune response to lymphoma tumor-antigen se70-2 after treatment. Our study shows that intralesional injections of TG1042 are both safe and well tolerated...
  19. ncbi Inhibition of tumor growth by recombinant vaccinia virus expressing GA733/CO17-1A/EpCAM/KSA/KS1-4 antigen in mice
    Jan Zaloudik
    The Wistar Institute, Philadelphia, Pennsylvania 19104, USA
    Cancer Gene Ther 9:382-9. 2002
    ..The combined vaccine approach may be superior to the use of either vaccine alone in patients who are pre-immune to both viruses...
  20. doi Intralesional adenovirus-mediated interleukin-2 gene transfer for advanced solid cancers and melanoma
    Reinhard Dummer
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Mol Ther 16:985-94. 2008
    ..Our results show that intratumoral injections of TG1024 are safe and well tolerated. The clinical activity of TG1024 observed in this study warrants further investigations...
  21. doi A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer
    Rodryg Ramlau
    Regional Center for Lung Disease, Wielkopolskie Centrum, Poznan, Poland
    J Thorac Oncol 3:735-44. 2008
    ..This vector is based on the modified virus of Ankara, a significantly attenuated strain of vaccinia virus. TG4010 has been designed to induce or amplify a cellular immune response directed against tumor cells expressing MUC1...
  22. ncbi Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer
    Christoph Rochlitz
    Department of Research, Kantonsspital Basel, Switzerland
    J Gene Med 5:690-9. 2003
    ..The objective of the present study was to determine the safety of the product and to define the dose of TG4010 to be used in further clinical trials...
  23. ncbi Tumor immunology and the Battle of Waterloo
    Bruce Acres
    Mol Cancer Ther 1:651-5. 2002